Moderna Therapeutics’ Stock Price Soared, Then Gave Back Its Gains in Two Consecutive Days To begin with, most, if not all, development-stage firms are yo-yo games played by day traders and investors whose strategies are buying low and selling high. These people also buy and sell on encouraging news and bad news; if their eyes happen to fall on any fundamental news.   One of …

Exelixis Announced Results from its CABOMETYX® Combination with Roche's TECENTRIQ® News announced by Exelixis (EXEL) about encouraging results from the combination of its product cabozantinib (CABOMETYX®) with Roche’s product atezolizumab (TECENTRIQ . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Regeneron Pharmaceuticals Stock is Rallying Regeneron Pharmaceuticals (REGN) stock outperformed last week gaining over $27. The stock’s soaring was not the outcome of the market’s outperformance, for several consecutive days, but because the . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Synopsis The way many bloggers are interpreting the quarterly and yearly biotech companies’ financial results seems unfair and has proven to be. Amgen Amgen (AMGN): The stock gained over $10 yesterday and is trading now at $231. Many bloggers continue to attack the firm, mourning the loss of their protective patents on its over 30 years’ old products and ignore the record . . . …

Nektar Therapeutics NKTR-214: A Blockbuster? Nektar Therapeutics (NKTR) published preclinical data of its immuno-oncology candidate NKTR-214 bempegaldesleukin (bempeg) succeeded in revealing the details of the drug’s actions that led to its successful outcome when used in monotherapy or in combination therapy in treating of various cancers.     The product, which is a CD122-preferential interleukin-2 . . . This content is for paid subscribers. Please click here to …

As the Market Seems to Soar Our Eyes Are on the Following Biotech Stocks: Amgen (AMGN): A rebounding is expected following an unwarranted decline.   Gilead Sciences (GILD): A lot of good news from the firm, including the firm’s investigational product remdesivir that demonstrated positive results in beating the coronavirus infection. Read yesterday's article posted

Gilead Stock Is UP Gilead Sciences' (GILD) provided its antiviral experimental drug remdesivir to physicians for a small number of patients infected with the 2019 novel coronavirus (2019-nCoV) as a possible emergency savior . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Vertex Beats Expectations in 2019 Vertex (VRTX) reported fourth-quarter and full-year 2019 financial results yesterday. The results beat analysts’ expectations about the last quarter and the whole year 2019. In the same report the firm’s full-year financial guidance promises a thrilling future for Vertex. The report indicated that the total GAAP and Non . . . This content is for paid subscribers. Please click here to …

Regenxbio, Moderna and Others Regenxbio (RGNX) announced several poster presentations including interim data from its Phase I/II trial of RGX-121 for the treatment of Mucopolysaccharidosis Type II (MPS II

Time to Remember Compugen The time has ripened for our readers and biotech investors to remember what we posted in the past years about Compugen (CGEN). The importance of the reminder is that the firm has taken a long time to bring its target discoveries and its targeted treatments into clinical trials whose preliminary results have demonstrated promise. Compugen

The EMA validated the MAA for the Gilead Investigational CAR T Product for MCL Kite, a Gilead (GILD) company, announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) of the investigational CAR T product KTE-X19 for adult patients with relapsed or refractory mantle cell lymphoma (MCL

Coronavirus On January 7, 2020, a novel coronavirus (2019-nCoV) was identified in humans in Wuhan City, Hubei Province, China. Additional cases have been found in the United States and in a growing number of countries around the world.    Coronaviruses are a family of viruses that can lead to respiratory illness, including Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). Coronaviruses are …

A Comprehensive Essay Part 3 In parts 1 and 2 of this comprehensive essay Vertex (VRTX) was the firm we used as a case in point to demonstrate successful criteria and strategies towards evaluating biotech firms. As a matter of fact, we use the histories of real firms in this essay for the sake of demonstrating the above without considering the Companies . . . …

In the NEWS: Coronavirus Yesterday the CDC announced the first US case of coronavirus which has killed 17 and sickened hundreds of people in China. According to officials the first US case is of a very healthy 30 year old male currently being isolated at a medical center outside Seattle, WA so as not to pose a threat of contamination to the public. The CDC …

Forty Seven On December 21, 2018 Prohost picked Forty Seven (FTSV) at $16.95 adding it to its Portfolio of biotech firms with solid scientific and non-scientific fundamentals. Forty Seven develops novel checkpoint therapies to activate macrophages in the fight against cancer. The firm targets the CD47 pathway to engage macrophages in fighting tumors.  Macrophages function as . . . This content is for paid subscribers. …

Outperforming Prohost Picks  January 16, 2020 at 11:30 am EST MRNA Trading at $21.35 UP $1.01 AMGN Trading at $243.50 UP $1.80 FTSV  Trading at $40.00 UP $3.20 RETA Trading at $217.01 UP $4.56 ALNY Trading at $119.26 UP $1.17 CGEN Trading at $5.96 UP $0.17 PTCT  Trading . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Nektar in the NEWS The FDA's Anesthetic and Analgesic Advisory Committee (AADPAC) and Drug Safety and Risk Management Advisory Committee (DSaRM) unanimously voted no regarding the approval of Nektar Pharmaceuticals’ (NKTR) New Drug Application (NDA) for its opioid product oxycodegol (formerly NKTR-181). In a short

A Comprehensive Essay Part 2 In Part 1 of our comprehensive essay series Vertex Pharmaceuticals (VRTX) was the first firm we used to make a case in point to demonstrate successful criteria and strategies towards evaluating biotech firms. In Part 2, Vertex . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

XBiotech XBiotech (XBIT), headquartered in Austin, Texas, develops innovative proprietary manufacturing technology that reduces the cost and complexity of biological drug production. XBiotech is dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies. The firm is currently advancing a pipeline of therapies by harnessing naturally occurring antibodies from patients with immunity to certain diseases. Indeed, XBiotech is utilizing natural human immunity . . . This content …

Nektar Therapeutics and Bristol-Myers Squibb Agreement Nektar Therapeutics (NKTR) and Bristol-Myers Squibb (BMY) announced their agreement for a new joint development plan aimed at advancing the combination of Nektar’s bempegaldesleukin (bempeg) + Bristol-Myers’ Opdivo (nivolumab) into multiple new registrational trials. The decision is based on a revision of the strategic collaboration agreement. It includes a new plan where both firms will expand the active clinical development …